1841 - 1850 of 9145 Results
Title
Year
- Classification of Parkinson's disease based on multi-modal features and stacking ensemble learning2020RESTRICTEDTitle: Classification of Parkinson's disease based on multi-modal features and stacking ensemble learningJournal Name: Journal of Neuroscience MethodsPublisher: Elsevier BVVol: 350Issue #:Start Page: 109019End Page: 109019Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jneumeth.2020.109019Citation Count: 79
-
OPENTitle: Effective R2 relaxation rate, derived from dual-contrast fast-spin-echo MRI, enables detection of hemisphere differences in iron level and dopamine function in Parkinson’s disease and healthy individualsJournal Name: Journal of Neuroscience MethodsPublisher: Elsevier BVVol: 382Issue #:Start Page: 109708End Page: 109708Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.jneumeth.2022.109708Best OA location URL: https://ars.els-cdn.com/content/image/1-s2.0-S0165027022002345-ga1_lrg.jpgCitation Count: 13
-
OPENTitle: Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesiclesJournal Name: CytotherapyPublisher: Elsevier BVVol: 23Issue #: 5Start Page: 373End Page: 380Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.jcyt.2021.01.001Best OA location URL: http://hdl.handle.net/11380/1251814Citation Count: 247
- Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease2022OPENTitle: Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s DiseaseJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 65Issue #: 24Start Page: 16801End Page: 16817Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acs.jmedchem.2c01605Citation Count: 24
- The protean roles of neuroinflammation in trauma, infections, autoimmunity and neurodegeneration2022RESTRICTEDTitle: The protean roles of neuroinflammation in trauma, infections, autoimmunity and neurodegenerationJournal Name: Seminars in ImmunologyPublisher: Elsevier BVVol: 61-64Issue #:Start Page: 101655End Page: 101655Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.smim.2022.101655Citation Count: 3
-
OPENTitle: Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imagingJournal Name: Seminars in Arthritis and RheumatismPublisher: Elsevier BVVol: 51Issue #: 5Start Page: 1125End Page: 1133Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.semarthrit.2021.08.004Best OA location URL: https://research.vumc.nl/en/publications/d083f460-428b-4cc9-b64c-8e646fc9a1c6Citation Count: 29
-
OPENTitle: An economic evaluation of the NightWatch for children with refractory epilepsy: Insight into the cost-effectiveness and cost-utilityJournal Name: Seizure: European Journal of EpilepsyPublisher: Elsevier BVVol: 101Issue #:Start Page: 156End Page: 161Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.seizure.2022.08.003Best OA location URL: http://www.seizure-journal.com/article/S1059131122001820/pdfCitation Count: 11
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial2021RESTRICTEDTitle: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trialJournal Name: Nature MedicinePublisher: Springer Science and Business Media LLCVol: 27Issue #: 8Start Page: 1451End Page: 1457Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s41591-021-01455-xCitation Count: 138
- Aducanumab: look before leaping2021RESTRICTEDTitle: Aducanumab: look before leapingJournal Name: Nature MedicinePublisher: Springer Science and Business Media LLCVol: 27Issue #: 9Start Page: 1499End Page: 1499Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s41591-021-01477-5Citation Count: 13
-
OPENTitle: Dopaminergic signalling limits suppressive activity and gut homing of regulatory T cells upon intestinal inflammationJournal Name: Mucosal ImmunologyPublisher: Elsevier BVVol: 14Issue #: 3Start Page: 652End Page: 666Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41385-020-00354-7Best OA location URL: https://www.nature.com/articles/s41385-020-00354-7.pdfCitation Count: 40
